Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

被引：0

作者：

Flinn, Ian ^{[1
]}

Brunvand, Mark ^{[2
]}

Dyer, Martin J. S. ^{[3
]}

Hillman, Peter ^{[4
]}

Jones, Jeffrey ^{[5
]}

Lymp, James ^{[6
]}

Elhamy, Mostafa ^{[6
]}

Vosganian, Gregory ^{[6
]}

Huang, Jane ^{[6
]}

Kipps, Thomas J. ^{[7
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Colorado Blood Canc Inst, Denver, CO USA

[3] Univ Leicester, Leicester, Leics, England

[4] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England

[5] Ohio State Univ, Sch Med, Columbus, OH 43210 USA

[6] Genentech Inc, San Francisco, CA 94080 USA

[7] Univ Calif San Diego, La Jolla, CA 92093 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)
Flinn, Ian W.
Brunvand, Mark
Choi, Michael Y.
Dyer, Martin J. S.
Gribben, John
Hillmen, Peter
Jones, Jeffrey
Li, Yan
Mobasher, Mehrdad
Vosganian, Gregory
Kipps, Thomas J.
BLOOD, 2015, 126 (23)
[2] Preliminary Results of a Phase 1b Study (GO28440) Combining GDC-0199 (ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Salles, Gilles Andre
Boyd, Thomas E.
Morschhauser, Franck
Wendtner, Clemens-Martin
Lymp, James
Hilger, James
Vosganian, Gregory
Huang, Jane
Stilgenbauer, Stephan
BLOOD, 2014, 124 (21)
[3] Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Salles, Gilles A.
Boyd, Thomas E.
Morschhauser, Franck
Wendtner, Clemens-Martin
Hallek, Michael
Eichhorst, Barbara F.
Kozloff, Mark
Cartron, Guillaume
Li, Yan
Hilger, James
Mobasher, Mehrdad
Stilgenbauer, Stephan
BLOOD, 2015, 126 (23)
[4] Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study
Ma, Shuo
Brander, Danielle M.
Seymour, John F.
Kipps, Thomas J.
Barrientos, Jacqueline C.
Davids, Matthew S.
Anderson, Mary Ann
Choi, Michael Y.
Tam, Constantine S.
Mason-Bright, Tanita
Prine, Betty
Munasinghe, Wijith
Zhu, Ming
Kim, Su Young
Humerickhouse, Rod A.
Roberts, Andrew W.
BLOOD, 2015, 126 (23)
[5] ABT-199 (GDC-0199) COMBINED WITH RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED / REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): INTERIM RESULTS OF A PHASE 1B STUDY
Roberts, A. W.
Ma, S.
Kipps, T.
Barrientos, J. C.
Davids, M. S.
Anderson, M. A.
Tam, C.
Mason-Bright, T.
Rudersdorf, N. K.
Yang, J.
Munasinghe, W.
Zhu, M.
Cerri, E.
Enschede, S. H.
Humerickhouse, R. A.
Seymour, J. F.
HAEMATOLOGICA, 2014, 99 : 249 - 249
[6] ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.
Ma, Shuo
Seymour, John Francis
Lanasa, Mark C.
Kipps, Thomas J.
Barrientos, Jacqueline Claudia
Davids, Matthew Steven
Mason-Bright, Tanita
Rudersdorf, Nikita
Yang, Jianning
Munasinghe, Wijith
Zhu, Ming
Cerri, Elisa
Enschede, Sari H.
Humerickhouse, Rod
Roberts, Andrew Warwick
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[7] VENETOCLAX (ABT-199/GDC-0199) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 1B RESULTS
Moreau, P.
Chanan-Khan, A. A.
Roberts, A.
Agarwal, A.
Facon, T.
Lebovic, D.
Touzeau, C.
Darden, D.
Morris, L.
Ross, J.
Salem, A.
Munasinghe, W.
Zhu, M.
Leverson, J.
Enschede, S.
Humerickhouse, R.
Harrison, S.
HAEMATOLOGICA, 2015, 100 : 91 - 92
[8] VENETOCLAX (ABT-199/GDC-0199) COMBINED WITH RITUXIMAB INDUCES DEEP RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Roberts, A. W.
Ma, S.
Brander, D.
Kipps, T. J.
Barrientos, J. C.
Davids, M. S.
Anderson, M. A.
Choi, M.
Tam, C.
Magee, L.
Kreutzer, J.
Singh, R.
Kim, J.
Dimovski, B.
Mason-Bright, T.
Prine, B.
Zhu, M.
Humerickhouse, R. A.
Seymour, J. F.
HAEMATOLOGICA, 2015, 100 : 154 - 154
[9] Venetoclax (ABT-199/GDC-0199) combined with rituximab induces deep responses in patients with relapsed/refractory chronic lymphocytic leukemia
Ma, Shuo
Roberts, Andrew W.
Brander, Danielle
Kipps, Thomas J.
Barrientos, Jacqueline C.
Davids, Matthew S.
Anderson, Mary Ann
Choi, Michael
Tam, Constantine
Magee, Lisa
Kreutzer, Jennifer
Kim, Jennifer
Dimovski, Belinda
Mason-Bright, Tanita
Prine, Betty
Zhu, Ming
Humerickhouse, Rod A.
Seymour, John F.
LEUKEMIA & LYMPHOMA, 2015, 56 : 21 - 21
[10] Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results
Kumar, Shaji K.
Vij, Ravi
Kaufman, Jonathan L.
Mikhael, Joseph R.
Facon, Thierry
Pegourie, Brigitte
Benboubker, Lotfi
Moreau, Philippe
Amiot, Martine
Alzate, Stefanie
Morris, Lura
Ross, Jeremy
Dunbar, Martin
Zhu, Ming
Maciag, Paulo
Agarwal, Suresh
Leverson, Joel
Enschede, Sari Heitner
Humerickhouse, Rod A.
Touzeau, Cyrille
BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →